2023年关于改善奥特罗亚新西兰心力衰竭患者管理的立场声明
Robert N Doughty1, Gerry Devlin2, Selwyn Wong3
1Heart Foundation Chair of Heart Health and Cardiologist, Department of Medicine, The University of Auckland; Greenlane Cardiovascular Service, Te Whatu Ora - Health New Zealand Te Toka Tumai, Auckland Hospital, Aotearoa New Zealand.
The New Zealand medical journal
|February 22, 2024
概括
迫切需要采取行动,以解决新西兰奥特亚罗的心力衰竭不平等问题. 本立场声明概述了最佳的医疗保健和药物治疗,以改善所有心力衰竭患者的健康结果.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 健康 公平 卫生 公平
背景情况:
- 心力衰竭影响人口的1-3%,是一个重大的公共卫生挑战,住院和死亡率高.
- 在过去的13年里,新西兰的心力衰竭发病率的健康不平等性在新西兰增加,不成比例地影响着毛利和太平洋人口.
- 当代心力衰竭管理指南提供了明确的指导,但公平获得最佳护理仍然是一个问题.
研究的目的:
- 确保公平获得最佳的医疗保健和以证据为基础的药物治疗,以在新西兰阿托亚罗亚为当代心力衰竭管理.
- 解决关键领域,包括获得药物治疗,及时启动和定位治疗,以及心力衰竭护理工作人员的能力.
主要方法:
- 这份立场声明综合了当前的区域和国际心力衰竭指南.
- 它重点关注三个关键领域:获得基于证据的药物治疗,早期启动和定位治疗,以及劳动力需求.
- 该方法强调实施基于证据的医疗保健策略.
主要成果:
- 该声明确定了改善心力衰竭护理的关键领域.
- 它强调需要公平地获得指导方针导向的医学治疗.
- 它强调了及时启动和定位治疗的重要性,并得到了足够的劳动力能力的支持.
结论:
- 实施基于证据的医疗保健策略对于改善新西兰的心力衰竭患者的结果至关重要.
- 解决健康不平等问题需要针对药物治疗的准入,治疗的及时性和医疗保健工作人员发展采取有针对性的行动.
- 确保最佳的医疗保健服务将为所有心力衰竭患者提供大幅改善健康的机会.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
01:22Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
01:22Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
01:26Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K